Breye Therapeutics ApS is featured on the latest episode of OptimumTV!

CEO Ulrik Mouritzen joined Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study of orally administered hashtag#danegaptide, for the treatment of diabetic retinopathy (DR). Danegaptide is being developed as a first in class oral small molecule therapy designed to offer a more effective and far less invasive treatment solution for earlier treatment intervention in patients with diabetic retinopathy.

Read more about Breye Therapeutics here

Get in touch with us

Johan Kördel

Ph.D., Managing Partner

Latest news

AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer

2025.09.022025.09.02 / Stockholm, Sweden, September 2, 2025 - AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces to ...

At home in the long, thorny transition from research to product launch

2025.09.012025.09.02 / After almost a decade as a research scientist and then another in pharmaceutical business development and product launch, Anna Gran has unparalleled insight for getting novel therapies to market. At ...

Breye Therapeutics ApS is featured on the latest episode of OptimumTV!

2025.08.212025.08.21 / CEO Ulrik Mouritzen joined Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study of orally administered hashtag#danegaptide, for the treatment ...